Document is current

Article History

Received: 2 March 2022

Revised: 13 June 2022

Accepted: 27 June 2022

First Online: 21 July 2022

Declarations

:

: D.S.M. reports institutional research grants from PharmaMar, Eisai, Immix BioPharma and Novartis outside the submitted work; travel support from PharmaMar, Eisai, Celgene, Bayer and Pfizer. F.R. reports speaker, consultancy or advisory role fees from Roche, BMS, MSD, Merck, Novartis, AstraZeneca, Pfizer, Lilly, Amgen, Pierre-Fabre, Incyte, Daichii-Sankyo, Bayer and Janssen. NH reports grants, personal fees and non-support from PharmaMar, research grants from Eisai, Immix BioPharma and Novartis outside the submitted work and re-search funding for clinical studies (institutional) from PharmaMar, Eli Lilly and Company, AROG, Bayer, Eisai, Lixte, Karyopharm, Deciphera, GSK, Novartis, Blueprint, Nektar, Forma, Amgen and Daichii-Sankyo. J.M.-B. reports research grants from PharmaMar, Eisai, Immix BioPharma and Novartis outside the submitted work; honoraria for advisory board participation and expert testimony from PharmaMar, honoraria for advisory board participation from Eli Lilly and Company, Bayer and Eisai; and research funding for clinical studies (institutional) from PharmaMar, Eli Lilly and Company, AROG, Bayer, Eisai, Lixte, Karyopharm, Deciphera, GSK, Novartis, Blueprint, Nektar, Forma, Amgen and Daichii-Sankyo. All other authors declare that there is no conflict of interest.

: Patients enrolled in the trial (Clinical Trial.gov number NCT02066285, and the European Union Drug Regulating Authorities Clinical Trials, number EUDRACT 2013-005456-15) consented to participate in the translational study presented here and signed an informed consent. Procedures were performed in accordance with guidelines established by the hospitals’ Ethics Committee, as well as in conformance with the Declaration of Helsinki.

: Informed consent was obtained from all individual participants included in the GEIS-32 clinical trial (ClinicalTrials.gov number NCT02066285 and European Union Drug Regulating Authorities Clinical Trials (EUDRACT), number 2013-005456-15).

: Not applicable.